LSE:GSK
GSK plc · LSE · Healthcare · GBP · FY for 2025
Figures on this page computed 2026-11-08 13:30 UTC
Last close
n/aGBp
Market data
13.4xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
- Computed from the filing for 2025
19.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
17.5%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
18.2%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
1.08Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- Computed from the filing for 2025
- Computed from the filing for 2025
3.3%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- GBp
- computed
Safety is the furthest below its sector's middle: 0.41 against 0.57 on the market's range.
Ten years as a story
lens 9 of 9We hold no filed year for this company, so there is nothing to read.
Nothing is drawn in its place. The other lenses are unaffected.